Literature DB >> 9074900

Disposition of 3H-labelled buserelin continuously infused into rats.

N Heinrich1, E Albrecht, J Sandow, U Kertscher, D Lorenz, J Oehlke, H Berger.   

Abstract

The disposition of the gonadotropin-releasing hormone (GnRH) agonist buserelin was studied in male rats under conditions of long-term administration. Rats were continuously infused with about 30 pmole [3H]-buserelin/24 h subcutaneously by osmotic minipumps for 4-7 days. After killing the rats, the 3H-activity of the tissues was measured and was found to be highly concentrated (about 10-fold to plasma) only in the pituitary. The daily amounts of 3H-activity excreted in urine and faces were constant over the whole infusion period, suggesting steady state conditions. On a molar basis, of the infused dose of buserelin, 14.8% was found to be excreted into urine as intact peptide, and 16.5, 10.8 and 20.6% as the partial buserelin sequences 1-2, 1-3 and 5-9. It is concluded that the major elimination route of buserelin, constant with time, is glomerular filtration, followed by enzymatic degradation of part of the filtered peptide by kidney tubuli enzymes to the partial sequences 1-2, 1-3 and 5-9, which reflects the proteolytic breakdown of buserelin by kidney membrane peptidases in vitro. Based on the similarities in the pharmacokinetics, in vivo metabolities, and in vitro enzymatic degradabilities among the GnRH agonists that have the native GnRH sequence modified at position 6 with or without additional modification at the C-terminal, the elimination process as shown here for buserelin should also be valid for other GnRH agonists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9074900     DOI: 10.1007/BF03189737

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

Review 1.  Clinical applications of gonadotropin-releasing hormones in reproductive disorders.

Authors:  K S Moghissi
Journal:  Endocrinol Metab Clin North Am       Date:  1992-03       Impact factor: 4.741

2.  The metabolism of neuropeptides. Hydrolysis of peptides by the phosphoramidon-insensitive rat kidney enzyme 'endopeptidase-2' and by rat microvillar membranes.

Authors:  S L Stephenson; A J Kenny
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

3.  Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.

Authors:  H Berger; J Sandow; N Heinrich; E Albrecht; U Kertscher; J Oehlke
Journal:  Drug Metab Dispos       Date:  1993 Sep-Oct       Impact factor: 3.922

4.  Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.

Authors:  Y Igari; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

5.  Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.

Authors:  N I Chu; R L Chan; K M Hama; M D Chaplin
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

6.  Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.

Authors:  R L Chan; M D Chaplin
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

7.  Pathways of degradation of buserelin by rat kidney membrane.

Authors:  U Kertscher; M Brudel; B Mehlis; J Sandow; H Berger
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

8.  Effects of D-amino acid substituents on degradation of LHRH analogues by proximal tubule.

Authors:  G Flouret; T Majewski; D R Peterson; A J Kenny; F A Carone
Journal:  Am J Physiol       Date:  1987-03

9.  Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo.

Authors:  C J Molineaux; A Lasdun; C Michaud; M Orlowski
Journal:  J Neurochem       Date:  1988-08       Impact factor: 5.372

10.  Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.

Authors:  L Kiesel; J Sandow; K Bertges; G Jerabek-Sandow; H Trabant; B Runnebaum
Journal:  J Clin Endocrinol Metab       Date:  1989-06       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.